Between January and March 2019, Russia imported 125.5 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices), which is in monetary terms (rubles) 8.5% higher than that of the same period in 2018, and 30 bln RUB worth of in-bulk drugs, which is in monetary terms 24.4% higher than that of the same period in 2018. The total dynamics are +11.3% for the period.

Between January and April 2019, Russia produced 127.4 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms (rubles) 26.3% higher than that of the same period in 2018. These high dynamics are due not only to inflation but also to high production volume in physical terms (+4.1%).

Earlier this year, the market saw a renewed growth in monetary terms and the long forgotten double-digit, which looks very impressive in contrast with the moderate results of 2018. However, the dynamics were mostly achieved by the state segment due to the events far from unexpected or inexplicable in the industry. As for retail, the dynamics were just beyond the inflation rates, while the actual demand continues to drop, which is logical due to income decline of the population.

Between January and April 2019, Russia imported over 3.6 bln RUB worth of pharmaceutical drugs made in the EEU countries (wholesale prices, VAT included), which is in monetary terms (rubles) 37.8% higher than that of the same period in 2018. In physical terms (units), the dynamics are +46.3%, with 85.4 mln units of pharmaceuticals.